Our glioma-specific drug sensitivity analysis has been conducted further in this section and demonstrated that overexpressed ELF4 might elevate the response to veliparib, motesanib, and EHT 1864 in gliomas. The gene discussed is ELF4; the disease is central nervous system cancer.